Interleukin-2 receptor-targeted fusion toxin using parts of the diphtheria toxin data

SRGN (Hopkinton, Mass.) reported additional data from its Phase I/II trial, showing a significant decrease in disease severity scores.

As presented at a recent conference on novel immune therapies, scores decreased from baseline by a mean of 32 percent (p=0.0001) in 18 patients who completed at least two courses. ...